New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
09:03 EDTMNKMallinckrodt to present new data for Xartemis XR, Pennsaid 2%
Mallinckrodt will present new data for two of its recently approved pain medications XARTEMIS XR Extended-Release Tablets and PENNSAID 2% during the 33rd Annual Scientific Meeting of the American Pain Society to be held April 30 - May 3, 2014 in Tampa, Florida. XARTEMIS XR is an oral medication indicated for the management of acute pain severe enough to require opioid treatment in patients for whom alternative treatment options are ineffective, not tolerated or would otherwise be inadequate. It is the first and only oxycodone HCI/acetaminophen combination for acute pain with immediate- and extended-release analgesia, providing fast-acting and long-lasting pain relief with 12-hour dosing for patients. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for the treatment of the pain of osteoarthritis of the knee(s). The data to be presented on XARTEMIS XR evaluates pharmacokinetics in different populations, as well as pooled safety data from Phase III trials. The first presentation of pivotal efficacy and safety results for PENNSAID 2% in the treatment of pain for osteoarthritis of the knee will also be presented, as well as an assessment of pharmacokinetics and tolerability compared with the 1.5% PENNSAID formulation.
News For MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:24 EDTMNKJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
May 15, 2015
09:31 EDTMNKAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use